Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Journalist working with Al Jazeera killed in Israeli Gaza strike, network says Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a ...

Join Drs Steven Feldman and Jules Lipoff as they discuss teledermatology, the cost of prescriptions, and other barriers to ...

Moore, who like the EMTs was decked out in personal protective equipment, kept out of their way as he tried to respectfully take photos of the life-threatening situation. Unfortunately ...

Moderate to severe scalp psoriasis severely affects quality of life, with high DLQI scores and significant symptoms like itch, pain, and flaking. Deucravacitinib, a tyrosine kinase 2 inhibitor ...

and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and ...

statements regarding the potential of ZORYVE foam and regulatory timing for FDA approval based on the PDUFA for the treatment of scalp and body psoriasis, the potential for clinical results for ...